

**South East London Area Prescribing Committee
Formulary recommendation**

Reference	015															
Intervention:	Aripiprazole (Abilify Maintena®) depot injection for the treatment of schizophrenia (Aripiprazole is a second generation antipsychotic)															
Date of Decision	September 2014															
Date of Issue:	October 2014															
Recommendation:	Amber – Specialist initiation and supply. GPs may be asked to take on prescribing under a full shared care agreement.															
Further Information	<ul style="list-style-type: none"> Aripiprazole depot injection is approved in line with its licensed indication* for use in patients with schizophrenia who are intolerant of and non-compliant with other antipsychotic drugs, where the use of other antipsychotic drugs cannot be clinically justified. *Aripiprazole is licensed for the maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole Patients must be stable for 12 months after which transfer to primary care can be considered under a shared care arrangement. Written support material will be provided to the patient to aid decision making around choice of antipsychotic agent Individual CCGs may need to discuss implementation of this recommendation at a local level. In particular its impact on pathways for commissioning mental health services and staff education/training. 															
Shared Care/ Transfer of care required:	Yes															
Cost Impact for agreed patient group	<table border="1" data-bbox="466 1308 1434 1532"> <thead> <tr> <th>Drug</th> <th>Maintenance dose</th> <th>Cost per year (excl VAT)</th> </tr> </thead> <tbody> <tr> <td>Aripiprazole</td> <td>400mg monthly</td> <td>£2645</td> </tr> <tr> <td>Risperidone</td> <td>25-50mg every 2 weeks</td> <td>£2072 to 3712</td> </tr> <tr> <td>Paliperidone palmitate</td> <td>25-150mg monthly</td> <td>£2207² to 4711</td> </tr> <tr> <td>Clanzapine pamoate monohydrate</td> <td>150-300mg every 2 weeks or 300-405mg every 4 weeks</td> <td>£2894 to 5789</td> </tr> </tbody> </table> <ul style="list-style-type: none"> The evidence evaluation considered by the New Drugs Panel states that the manufacturer estimates 15,245 people in England are currently receiving a second-generation prolonged-release antipsychotic for maintenance treatment for schizophrenia. They predict that 4% of those eligible for treatment with these drugs will receive aripiprazole depot injection in year 1 rising to 8% in year 2 and 12% in year 3. Based on population in SE London of 1.8 million, this would equate to 20 people (or 1 person per 100,000 population) receiving aripiprazole depot in the first year rising to 40 in year 2 and 60 in year 3. This would result in a cost impact of around £53,000 across SEL in year 1. This excludes any service delivery related costs. 	Drug	Maintenance dose	Cost per year (excl VAT)	Aripiprazole	400mg monthly	£2645	Risperidone	25-50mg every 2 weeks	£2072 to 3712	Paliperidone palmitate	25-150mg monthly	£2207 ² to 4711	Clanzapine pamoate monohydrate	150-300mg every 2 weeks or 300-405mg every 4 weeks	£2894 to 5789
Drug	Maintenance dose	Cost per year (excl VAT)														
Aripiprazole	400mg monthly	£2645														
Risperidone	25-50mg every 2 weeks	£2072 to 3712														
Paliperidone palmitate	25-150mg monthly	£2207 ² to 4711														
Clanzapine pamoate monohydrate	150-300mg every 2 weeks or 300-405mg every 4 weeks	£2894 to 5789														
Usage Monitoring & Impact Assessment	<p>Acute Trusts:</p> <ul style="list-style-type: none"> Submit usage data on request for the APC annual report. Ensure shared care guideline is provided and adhered to, provide audit data and data on outcomes upon request for reporting back to the APC. 															

	<ul style="list-style-type: none"> • CCGs. Monitor EPACT data. • Exception reports from GPs if inappropriate transfer of prescribing to primary care is requested.
Evidence reviewed	References <ol style="list-style-type: none"> 1. Otsuka Pharmaceuticals (UK) Ltd. Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection. SPC (date of revision of the text 28 March 2014). http://www.medicines.org.uk/emc/medicine/28494/SPC/Abilify+Maintena+400+mg+powder+and+solvent+for+prolonged-release+suspension+for+injection/ 2. Scottish Medicines Consortium. Aripiprazole 400mg powder and solvent for prolonged release suspension for injection (Abilify Maintena®): SMC No. (962/14) issued 04 April 2014. http://www.scottishmedicines.org.uk/SMC_Advice/Advice/962_14_aripiprazole_Abilify_Maintena/aripiprazole_Abilify 3. NICE. Schizophrenia: aripiprazole prolonged-release suspension for injection, ESNM39: published 26 March 2014. http://publications.nice.org.uk/esnm39-schizophrenia-aripiprazole-prolonged-release-suspension-for-injection-esnm39#close 4. Anon. Second-generation long-acting injectable antipsychotic agents: an overview. DTB 2012 50: 102-105 5. NICE. Psychosis and schizophrenia in adults: treatment and management. Clinical guideline 178 (issued: February 2014, last modified: March 2014): http://www.nice.org.uk/nicemedia/live/14382/66534/66534.pdf 6. Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, Leucht S, Xia J. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD006569. DOI: 10.1002/14651858.CD006569.pub5. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006569.pub5/abstract 7. Janssen-Cilag Ltd. Risperdal Consta 25, 37.5 and 50 mg powder and solvent for prolonged-release suspension for intramuscular injection. SPC (date of revision of text November 2013). http://www.medicines.org.uk/emc/medicine/9939/SPC/RISPERDAL+CONSTA+25%2c+37.5+and+50+mg+powder+and+solvent+for+prolonged-release+suspension 8. Eli Lilly and Company Limited. Zypadhera 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection. SPC (date of revision of text 25 April 2014) http://www.medicines.org.uk/emc/medicine/21361/SPC/ZYPADHERA+210+mg%2c+300+mg%2c+and+405+mg%2c+powder+and+solvent+for+prolonged+release+suspension+for+injection/#INDICATIONS 9. Janssen-Cilag Ltd. Xeplion 50 mg, 75 mg, 100 mg and 150 mg prolonged release suspension for injection. SPC (date of revision of the text 03 December 2013). http://www.medicines.org.uk/emc/medicine/24403/SPC/XEPLION+50+mg%2c+75+mg%2c+100+mg+and+150+mg+prolonged+release+suspension+for+injection/#INDICATIONS 10. Kirson N.Y., Weiden P.J., Yermakov S., et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: Synthesizing results across different research designs. J Clin Psychiatry, 2013; 74: 568-575 11. UKMI patents database accessed 09 June 2014 12. Drug tariff accessed online 10 June 2014

NOTES:

- a) Area Prescribing Committee recommendations and minutes are available publicly on member CCG websites.
- b) This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if new data becomes available, costs are higher than expected or new NICE guidelines or technology appraisals are issued.
- c) Not to be used for commercial or marketing purposes. Strictly for use within the NHS